交易 Summit Therapeutics Inc - SMMT 差价合约

交易条件

• 类型: 差价合约
• 点差: 0.11
• 长仓隔夜仓息调整: -0.02154%
• 短仓隔夜仓息调整: -0.00068%
• 隔夜调整仓息时间: 22:00 (UTC)
• 货币: USD
• 最低成交量: 0.1
• 保证金: 50.00%
• 证券交易所: United States of America
• 交易佣金: 0%
• 保证止损溢价: 1%

主要统计数据

• 前收盘价: 14.92
• 开仓: 14.69
• 1 年变化: -26.62%
• 日区间: 14.67 - 15.01

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States, Latin America, and Europe. It conducts clinical programs focusing on the Clostridioides difficile infection (CDI). The company''s lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also develops DDS-01 series to treat infection caused by the bacteria Neisseria gonorrhoeae through Discuva platform; and DDS-04 series to treat Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.